RGLS
$0.49
Regulus Therapeutics
($.04)
(7.11%)
RGLS
Earnings Whisper ®
N/A
3rd Quarter September 2021
Consensus:  ($0.07)
Revenue:  $0.02 Mil
Tuesday
Nov 9
4:05 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when RGLS reports earnings?
Beat
Meet
Miss

Where is RGLS's stock price going from here?
Up
Flat
Down
Stock chart of RGLS
Analysts
Summary of analysts' recommendations for RGLS
Score
Grade
Pivots
Resistance
$0.56
$0.54
$0.51

$0.49

Support
$0.47
$0.45
$0.42
Tweet
Growth
Description
Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs, called microRNA therapeutics. The Company's products aim to treat or prevent hepatitis C infections, cardiovascular disease, fibrosis, oncology, immuno-inflammatory diseases, and metabolic diseases. Regulus Therapeutics Inc. is based in La Jolla, California.
Peers
Vertex PharmaceuticalsUltragenyx PharmaceuticalRegeneron PharmaceuticalsBioMarin PharmaceuticalBristol-Myers SquibbInterCeptMerck & Co.Eli LillyZoetisPfizer